Insmed CMO exercises options, sells 12,302 shares
INSMED Inc's Chief Medical Officer, Martina Flammer, reported an exercise-and-sell transaction in company stock.
Rhea-AI Filing Summary
INSMED Inc's Chief Medical Officer, Martina Flammer, reported an exercise-and-sell transaction in company stock. She exercised stock options to acquire a total of 12,302 shares of common stock at strike prices of $19.74 and $29.13 per share, then sold the same 12,302 shares in open-market trades at weighted average prices of $110.60 and $109.02 per share. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025, and she now holds 60,486 shares of common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 12,302 shares ($1.04M approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Flammer Martina M.D.
Role
Chief Medical Officer
Sold
12,302 shs ($1.35M)
Approx. gross sale proceeds
$1.35M
Approx. exercise cost
$317K
Approx. pre-tax spread
$1.04M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 7,945 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 4,357 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,945 | $29.13 | $231K |
| Exercise | Common Stock | 4,357 | $19.74 | $86K |
| Sale | Common Stock | 4,854 | $109.02 | $529K |
| Sale | Common Stock | 7,448 | $110.60 | $824K |
Holdings After Transaction:
Stock Option (right to buy) — 28,193 contracts (Direct);
Common Stock — 60,486 shares (Direct)
Footnotes (4)
- F1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2. This is the weighted average sales price representing 4,854 shares sold at prices ranging from $108.90 to $109.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F3. This is the weighted average sales price representing 7,448 shares sold at prices ranging from $110.36 to $110.71 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F4. The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Key Figures
Shares sold: 12,302 shares
Sale price tranche 1: $110.60/share
Sale price tranche 2: $109.02/share
+5 more
8 metrics
Shares sold
12,302 shares
Total common shares sold in open-market transactions on July 6, 2026
Sale price tranche 1
$110.60/share
Weighted average for 7,448 shares sold
Sale price tranche 2
$109.02/share
Weighted average for 4,854 shares sold
Options exercised (lot 1)
4,357 shares at $19.74/share
Common stock acquired via option exercise
Options exercised (lot 2)
7,945 shares at $29.13/share
Common stock acquired via option exercise
Post-transaction holdings
60,486 shares
Common stock directly owned after all reported transactions
Trading plan adoption date
February 27, 2025
Date Rule 10b5-1 trading plan was adopted
Option expiration dates
2033-01-05 & 2034-01-04
Expiration for the exercised stock option grants
Key Terms
Rule 10b5-1 trading plan, open-market sale, Stock Option (right to buy), Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
vesting schedule financial
"The options become exercisable based on the following vesting schedule"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did INSMED (INSM) report for its Chief Medical Officer?
INSMED’s Chief Medical Officer, Martina Flammer, exercised stock options for 12,302 common shares and sold all 12,302 shares in open-market transactions. The activity reflects an exercise-and-sell pattern rather than a new open-market purchase of shares.
What stock options did the INSMED (INSM) CMO exercise in this Form 4?
She exercised options covering 4,357 shares at a strike price of $19.74 and 7,945 shares at a strike price of $29.13. These exercises converted derivative stock options into common shares before the subsequent open-market sales.
Were the INSMED (INSM) insider sales made under a Rule 10b5-1 plan?
Yes. The Form 4 states the transactions were executed under a Rule 10b5-1 trading plan adopted on February 27, 2025. Such plans pre-schedule trades, indicating the timing was predetermined rather than based on new, discretionary decisions.
What does the vesting footnote on the INSMED (INSM) stock options mean?
The footnote explains that 25% of the options vest on the first anniversary of the grant date, with an additional 12.5% vesting every six months through the fourth anniversary. This schedule gradually makes more options exercisable over time as part of compensation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
